The record · filed by finding
The BPC-157 TB-500 research record, listed by constituent
Two peptides, two mechanisms, two decks of preclinical findings — and one missing entry: a controlled study of the combination.
BPC-157 and TB-500: The Two Peptides Behind the Wolverine Blend
BPC-157 and TB-500 are the two peptides behind the Wolverine blend, and they share almost nothing structurally. BPC-157 is a 15-amino-acid pentadecapeptide (GEPPPGKPADDAGLV, ~1419 Da) derived from a human gastric-juice protein. TB-500 is a 7-amino-acid acetylated fragment (Ac-LKKTETQ, ~889 Da) of the 43-residue protein Thymosin Beta-4 [3]. They are filed in the same blend because their proposed mechanisms are complementary, not because they are chemically related.
The combination rationale is straightforward to state and important to bound. BPC-157 acts locally and vascularly; TB-500 acts intracellularly on the actin cytoskeleton. Proponents pair them to cover angiogenesis and cell migration at once. The published record characterizes each mechanism on its own — it has never characterized the two acting together, so the combination remains a rational hypothesis rather than a demonstrated effect [9].
What BPC-157 and TB-500 Have Been Studied For
BPC-157 and TB-500 benefits, as they appear in the literature, are tissue-repair findings in animals. The flagship BPC-157 result is tendon: at 10 microg/kg or 10 ng/kg intraperitoneally, BPC-157 accelerated healing of a fully transected rat Achilles tendon across load-to-failure, collagen organization, and functional recovery, and in vitro it reversed 4-hydroxynonenal-induced growth inhibition of tendocytes into stimulation [1]. BPC-157 has also protected liver, kidney, and lung against distant-organ damage in a 2025 rat ischemia-reperfusion model, extending its cytoprotection beyond the injury site [12].
The TB-500 side is carried largely by full-length Thymosin Beta-4. In a rat full-thickness wound model, Thymosin Beta-4 raised re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline, and increased wound contraction, collagen deposition, and angiogenesis [5]. Thymosin Beta-4 also promoted angiogenesis, wound healing, and hair-follicle development in normal and aged rodents [7]. Filed honestly: these are constituent benefits, not blend outcomes.
How BPC-157 Drives Angiogenesis (VEGFR2-Akt-eNOS)
BPC-157's vascular mechanism is the better-defined of the two legs. It up-regulates VEGFR2 expression and promotes VEGFR2 internalization, with downstream activation of the VEGFR2-Akt-eNOS pathway [2]. The functional consequences in animal models are increased vessel density and accelerated blood-flow recovery in ischemic muscle, and the effect is abolished when receptor endocytosis is blocked — evidence that the receptor trafficking is mechanistically load-bearing, not incidental [2].
Beyond VEGFR2, the BPC-157 literature describes modulation of the nitric-oxide system and growth-hormone-receptor up-regulation in tendon fibroblasts, the latter tying the angiogenic story back to the tendon-repair finding [1][2]. This is the cytoprotective, pro-angiogenic leg the blend rationale assigns to BPC-157.
TB-500, Actin and Thymosin Beta-4
TB-500 is the Ac-LKKTETQ fragment of Thymosin Beta-4. X-ray crystallography established that Thymosin Beta-4 forms a 1:1 complex with monomeric G-actin and sequesters it by capping both ends, regulating the cytoskeletal dynamics that drive cell migration and re-epithelialization [3].
How TB-500 Works: G-Actin Sequestration
TB-500's mechanism is structural and intracellular. X-ray crystallography of a gelsolin-domain-1-Thymosin Beta-4 hybrid bound to actin, resolved to 2 angstroms, established that Thymosin Beta-4 forms a 1:1 complex with G-actin and sequesters the monomer by capping both ends, preventing polymerization [3]. That is the structural basis for the actin-buffering activity attributed to the LKKTETQ motif TB-500 carries.
A consolidated review extends the picture: Thymosin Beta-4 binds actin and promotes cell mobilization and migration, decreases myofibroblast number (reducing scar formation), is released by platelets and macrophages after injury to limit apoptosis and inflammation, and promotes angiogenesis [4]. Thymosin Beta-4 also stimulated hair growth in rats and mice at nanomolar concentrations by activating hair-follicle bulge stem cells [6]. The caveat repeats: most of this is full-length Thymosin Beta-4, not the TB-500 heptapeptide.
Is the Synergy Claim Proven?
The BPC-157 + TB-500 stack, as a combined intervention, has no controlled evidence behind it. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for the two peptides given together [9]. The 2025 HSS Journal systematic review of BPC-157 — 36 studies, only 1 of them human, with an explicit finding of "no clinical safety data" — does not mention TB-500 or combination use anywhere [9]. "Synergy" is an extrapolation from each peptide's separate mechanism, nothing more.
The broader regulatory and safety reviews reinforce the bound. A 2026 Sports Medicine narrative review lists both BPC-157 and TB-500 among unapproved peptides that show favorable tissue-repair outcomes in animal models but lack rigorous human safety data and operate largely outside regulatory oversight [10]. A 2025 narrative review of BPC-157 concludes that human data are limited to three small pilot studies and that the compound should be considered investigational [11]. The combination inherits both peptides' evidence gaps and adds a new one.
The BPC-157 + TB-500 Stack: Combined-Use Rationale and Evidence Gap
The stack pairs BPC-157's angiogenic leg with TB-500's cell-migration leg on the theory that they cover different repair stages. No combination study defines a ratio, dose, or endpoint, and a 36-study BPC-157 review never mentions TB-500 [9]. The rationale is mechanistic; the combined evidence is absent.
Is the Synergy Claim Proven?
No. No peer-reviewed study has defined a synergy ratio, dose, or endpoint for the two given together. A 2025 systematic review of BPC-157 (36 studies, only 1 human, "no clinical safety data") makes no mention of TB-500 or combination use [9]. Synergy is an extrapolation from each peptide's separate mechanism.
Human Trials on the Combination
None. There are no controlled clinical trials of the BPC-157 + TB-500 combination for any indication. Human data exist only for the individual constituents and are thin: BPC-157 has three small pilot studies [11], and "TB-500" human data are for full-length Thymosin Beta-4, not the heptapeptide [4].
Tendon and Ligament Findings
In animal models, BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, and microscopic measures and stimulated tendocyte growth in vitro [1]. These are preclinical, single-compound results, not human or combination evidence.
Muscle Repair Findings
Preclinical work attributes tissue-repair and cell-migration activity to both constituents in animal models [1][4], but findings are single-compound and the blend itself has no controlled muscle-recovery trial. Online "rapid healing of any injury" claims outrun the published, animal-model evidence [10].